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The Advisory Council on the Misuse of Drugs (ACMD) has undertaken a 
review of naloxone availability in the UK, presented in the attached report. 
The purpose of the report is to provide Government with advice on whether 
naloxone should be made more widely available, in order to prevent future 
drug-related deaths, and help engage and educate those most vulnerable of 
suffering an opioid overdose.  
 
The evidence we present in the report shows that naloxone provision reduces 
rates of drug-related death. Evidence also shows that training in all aspects of 
overdose response is important alongside naloxone provision, and benefits 
both service users and carers. Naloxone is already available on prescription 
to people at risk of opioid overdose, such as heroin users. However, 
maximum impact on drug-related death rates will only be achieved if naloxone 
is given to people with the greatest opportunity to use it, and to those who can 
best engage with heroin users.  
 
The efficacy of naloxone is not in dispute. Naloxone is a WHO-recommended 
medicine, and efficacy has been proven in several published studies and 
pilots. Naloxone is a safe, effective drug, with no dependence-forming 
potential. Its only action is to reverse the effects of opioid overdoses, and it is 
already used by emergency services personnel in the UK for this purpose. 
Despite recent falls in the number of deaths attributable to heroin overdose, 
we find that many of these fatalities are preventable by the use of naloxone as 
an intervention.   
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Naloxone provision is aligned with the Drug Strategy aim of preventing drug-
related deaths, which is one of eight key outcomes for delivery in a recovery-
orientated drug treatment system. Continued use of local public health 
interventions like overdose prevention training and naloxone provision is 
important to improve people’s health, and maximise their chances of recovery 
from drug dependence. In this context we find it positive that naloxone 
provision can increase people’s engagement with drug treatment services. 
 
Critics have suggested that naloxone provision in the community could 
encourage people to use drugs more dangerously, if they know naloxone is 
available. The ACMD is not aware of any significant body of evidence that 
naloxone provision encourages increased heroin use.  
 
Naloxone has been provided locally to service users and carers for some 
years in the UK. In Scotland and Wales, recent successful pilots have led to 
national programmes.  The NTA in England ran a naloxone and overdose 
programme for families and carers, but there has been no similar roll-out. Last 
year, the Scottish Lord Advocate allowed naloxone to be provided to some 
services without prescription, for use in an emergency. This is commendable 
because Scottish drug treatment and homeless hostel staff can now hold it 
ready for use, and that Scottish medical professionals supplying naloxone are 
protected in cases of liability.  
 
The ACMD concludes that naloxone provision is an evidence-based 
intervention, which can save lives. Naloxone provision fits with other 
measures to promote recovery by encouraging drug users to engage with 
treatment services, and ultimately, keep them alive until they are in recovery. 
This report recommends actions for government to take to consider 
naloxone’s role in steps to make an impact on drug-related death rates. 
 
The production of this report has been aided by valuable contributions from 
several organisations and experts. The ACMD is particularly grateful to those 
experts who provided written and oral evidence.  
 




     
 
Professor Les Iversen    Professor Raymond Hill  
Chair, ACMD      Chair, Technical Committee 
ACMD      ACMD 
 
cc: Rt. Hon. Theresa May MP – Home Secretary  
Lord Henley – Minister of State for Crime Prevention and Antisocial Behaviour 
Reduction  
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1. Executive Summary 
 
1.1. The ACMD has been considering the issue of naloxone availability 
and provision, as an intervention to prevent drug-related deaths, 
since 2009 and has previously written to the Medicines and 
Healthcare products Regulatory Agency (MHRA) concerning 
provision. 
 
1.2. Naloxone is a safe, efficacious drug for reversing the effects of 
opioid overdoses. This report provides advice to the Government 
concerning the evidence and issue of making naloxone more 
widely available.   
 
1.3. In the UK, there are hundreds of deaths related to heroin use every 
year and a lesser number due to the abuse of other opioids.1 
Preventing drug-related deaths has been, and continues to be a 
priority for the Government. Naloxone is already used by 
emergency services personnel to reverse heroin and other opioid 
overdoses. In 2005, naloxone was made available under UK law to 
be administered by anyone for the purpose of saving a life. 
However, naloxone remains a prescription-only drug, and is only 
licensed for use in injectable form. This means that at present it is 
not able to be distributed to anyone without a named prescription. 
 
1.4. Because it is prescription-only, non-medical services which may 
experience frequent opiate-related overdoses are not able to 
legally hold stocks of naloxone to use in an emergency.  
 
1.5. There is evidence that take-home naloxone, given to service users 
and training carers or peers in how to administer naloxone, can be 
effective at reversing heroin overdoses. Wider provision of 
naloxone could result in a reduction in overall drug-related deaths 
in the UK. 
 
1.6. The ACMD believe that the single intervention of wider provision of 
naloxone is not sufficient in efforts to prevent future drug-related 
deaths. The Council considers itself aligned with UK and worldwide 
research that indicates that training service users, peers and carers 
in all aspects of how to respond to an overdose is important 
alongside naloxone provision.  
 
1.7. Scotland has already made provisions to make naloxone more 
widely available, through its 2011 Lord Advocate’s Guideline. This 
promotes the availability of naloxone to approved services without 
prescription, for use in an emergency. It also protects medical 
professionals supplying naloxone in cases of liability. 
 
                                                 
1
 The Office for National Statistics has reported at least 800 deaths due to drug poisoning with heroin 
mentioned on the death certificate in each year since 2000.  
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Recommendations are listed in brief below. For more details see section 
11. 
 
1.8. Recommendation 1: Naloxone should be made more widely 
available, to tackle the high numbers of fatal opioid overdoses in 
the UK. 
 
1.9. Recommendation 2: Government should ease the restrictions on 
who can be supplied with naloxone 
 
1.10. Recommendation 3: Government should investigate how people 
supplied with naloxone can be suitably trained to administer it in an 
emergency and respond to overdoses 
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2. Background  
 
2.1. The ACMD is established under the Misuse of Drugs Act 1971 
(hereafter termed the ‘Act’). Its purpose is to keep under review the 
drugs situation in the UK and provide advice to ministers. That 
advice may be concerned with; restricting availability, facilities and 
treatment (recovery), promoting co-operation between professional 
and community services, educating the public and promoting 
research.  
 
2.2. This report is concerned with advice on the supply and 
administration of the opioid antagonist naloxone. Naloxone rapidly, 
but temporarily, reverses the effects of heroin and other opioids. 
Naloxone has been distributed as part of emergency kits to heroin 
users worldwide for some years. This includes in England, 
Scotland, and Wales in the UK; and New York State, Los Angeles 
and Chicago in the USA. It has been distributed over the counter in 
pharmacies in Italy. 
 
2.3. International and UK research has found that naloxone provision 
may be effective at preventing opiate-related deaths. Wider benefits 
around engaging with drug users and empowering family members 
and carers is also reported. 
 
Heroin-related deaths in the UK 
 
2.4. Heroin has been the most widely-used opiate drug in the UK for 
some time (Home Office, 2011). It is estimated that there are 
approximately 380,000 problematic drug users (including heroin 
users) in the UK (Department of Health, 2011). Figures for the UK 
are unknown, but latest figures for England suggest there are 
264,072 opiate users (Hay et al., 2011). 
 
2.5. Heroin users are far more likely to die than peers of the same age 
and gender. Opiate overdoses are usually accidental, and most 
opiate users have experienced at least one non-fatal overdose. The 
risk of overdose is increased further in those recently released from 
prison (Bird et al., 2003; Farrell et al., 2007).  
 
2.6. Those who inject heroin are at increased risk of overdose and death 
(Gaston et al., 2009). Latest prevalence estimates for England 
indicate there are approximately 103,185 injectors (including those 
who inject other drugs such as cocaine). 
 
2.7. Heroin has contributed to over one thousand deaths in the UK in 
each of the last ten years. Deaths where heroin was mentioned on 
the death certificate represent a significant proportion (between a 
third and a half) of all deaths due to drug poisoning in the UK 
(Office for National Statistics, 2011; National Records of Scotland, 
2011; Northern Ireland Statistics and Research Agency, 2011).  
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2.8. Preventing drug-related deaths has been a Government priority 
over the last ten years. Numbers of drug-related deaths have 
significantly failed to reduce, and the English, Scottish, and Welsh 
governments have all implemented national naloxone pilots or 





2.9. The ACMD wrote to the MHRA in October 2009 welcoming the 
National Treatment Agency’s (NTA) naloxone programme 
announced earlier in 2009, which provided family members and 
carers overdose and naloxone training, and supplies of naloxone to 
heroin users (Annex A). 
 
2.10. This review, of the ACMD’s own volition, has been prompted by the 
growing body of evidence on the effectiveness of naloxone as a life 
saving provision to heroin users and carers, and also the benefits of 
engaging with the heroin using population, with regards to recovery.  
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3. Introduction and scope 
 
3.1. This review seeks to provide advice on making naloxone as widely 
available as possible in the UK, in order that it might have maximum 
impact on preventing opiate-related deaths. 
 
3.2. This review is not intended to address the efficacy of naloxone as a 
drug for reversing the effects of an opioid overdose – its efficacy is 
unquestionable: naloxone is recommended as an intervention to 
prevent overdose by the World Health Organisation as an essential 
medicine. The Global Fund to Fight AIDS, Tuberculosis, and 
Malaria recommends naloxone distribution as a component of 
comprehensive services for drug users (The Global Fund to Fight 
AIDS, Tuberculosis and Malaria, 2011). 
 
3.3. Naloxone (see Figure 1) is an opioid antagonist which rapidly, but 
temporarily, reverses the effects of heroin and other opioids. 
Importantly, amongst the effects of heroin that can be reversed is 




Figure 1: 17-allyl- 4,5α-epoxy- 3,14-dihydroxymorphinan- 6-one 
 
 
      
  
 
3.4. When injected intravenously naloxone acts very quickly, usually 
within a minute of administration, and its effects can last up to 45 
minutes. Its half-life is between 1 and 1.5 hours. Alternatively it can 
be injected subcutaneously or intramuscularly. It is available in 
intranasal formulations in the USA, but these are not licensed in the 
UK. Naloxone is marketed under a number of trademarks including 
Narcanti, Narcan and Nalone. Naloxone has a high affinity for μ-
opioid receptors in the central nervous system. 
 
3.5. Naloxone is a prescription-only medicine in the UK. It can be 
supplied to named individuals at risk of opioid overdose, via a 
prescription or a Patient Group Direction (PGD) or Patient Specific 
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Direction (PSD). Since naloxone has been allowed to be used by 
anyone for the purpose of saving a life under UK law in 2005, it has 
been provided via take-home programmes. It is reasonable for 
services to pilot take-home naloxone locally, with suitable training 
for its users – and for relatives and carers, if appropriate 
(Department of Health (England) and the devolved administrations, 
2007). 
 
3.6. The main aim of take-home naloxone programmes is to prevent and 
reduce opioid-related deaths. Such interventions are commonly 
associated with a wider spectrum of ‘harm reduction’ initiatives 
which have developed in the UK over the last decade.  
 
3.7. The UK drug treatment landscape has undergone recent changes, 
with the introduction of a new Drug Strategy. The Drug Strategy 
2010 notes that a fundamental difference between the strategy and 
those that have gone before, is that instead of focusing primarily on 
reducing the harms caused by drug misuse, the approach goes 
much further and offers every support for people to choose 
recovery as an achievable way out of dependency (HM 
Government, 2010). 
 
3.8. Preventing drug-related deaths (and blood-borne viruses) is the 
second of eight outcomes noted in the Drug Strategy, as key to 
successful delivery in a recovery-oriented treatment system. 
Preventing harm from drug use is a key public health issue, and 
preventing drug-related deaths remains a vital aspect of drug 
treatment provision. Interventions to support people as they move 
through treatment and recovery, including support if they relapse, 
remain important in the context of the Drug Strategy (HM 
Government, 2010). 
 
3.9. New NTA guidance to commissioners aims to help them develop 
local Joint Strategic Needs Assessments (JSNAs). It includes 
advice on preventing drug-related deaths in local areas, in support 
of the Drug Strategy outcomes. The guidance contains specific 
questions for commissioners when considering what success might 
look like in a recovery-oriented treatment system around drug-
related death prevention. A support pack promotes the benefits of 
continued investment; specifically including harm reduction.  
 
3.10. The ACMD has been considering naloxone provision for some time. 
The ACMD wrote to the MHRA in 2009, with the view that wider 
provision of naloxone to those likely to come into contact with, or 
caring for drug misusers, which is a specific and safe chemical, 
could provide benefits. The MHRA responded by stating it had no 
objections in principle to proposing changes to medicines 
legislations along these lines (Annex B). The MHRA sought the 
views of the Department of Health to establish if they supported a 
change in the law, to allow persons who may be in contact with 
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drug misusers to obtain supplies for use in an emergency, and to 
seek views on how such persons could be defined.  
 
3.11. The ACMD understands that the Department of Health were 
supportive, in principle, with optimising suitable access to naloxone 
supplies in an emergency. They stated that further consideration 
needed to be informed by the outcomes of the NTA overdose and 
naloxone programme for families and carers.   
 
3.12. The results of the NTA programme are now available. This report’s 
purpose is to provide consideration of this report, and other recent 
UK and international evidence on the effectiveness of naloxone 
provision. The report will provide recommendations on making 
naloxone more widely available to those who would be best placed 
to help people who have overdosed, in an attempt to prevent drug-
related deaths.   
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4. Current regulatory framework for prescribing naloxone 
 
4.1. Under the Medicines Act (1968), no-one, except individual patients 
with a prescription and appropriate medical practitioners (or those 
acting under medical instructions, including nurses), is allowed to 
administer parenteral (injectable) prescription-only medicines 
 
4.2. There is a limited list of exceptions to the restrictions of Section 7 of 
the Medicines Act. These include a number of injectable medicines 
that can be given by injection by anyone for the purpose of saving 
life in an emergency. The list includes adrenaline, atropine, 
glucagon, glucose and snake-venom antiserum.  
 
4.3. In June 2005, in the Medicines for Human Use (Prescribing) 
(Miscellaneous Amendments) Order, the United Kingdom added 
naloxone to that limited list of medicines. This means that currently: 
 
i. naloxone is an injectable, and therefore prescription-only, 
medicine that may be used by anyone for the purpose of saving 
life in an emergency;  
ii. naloxone can be prescribed directly to a patient, or supplied via 
a Patient Group Direction (PGD) or Patient Specific Direction 
(PSD); 
iii. prescribers should only prescribe and supply naloxone to a 
known patient with a medical condition that requires the 
medication, and with the patient’s informed consent; and, 
iv. naloxone cannot currently be prescribed (or supplied using a 
PGD/PSD) to a carer, peer, or member of staff on behalf of a 
drug user, and cannot be given to anyone without the drug 
user’s informed consent. 
 
4.4. These conditions mean that naloxone is restricted under 
prescription-only supply, and that supplies are not able to be held 
for general use on people in settings such as homeless hostels, or 
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5. Methods of administration 
 
5.1. Naloxone is most commonly administered intravenously or 
intramuscularly. It is common for users and carers to be trained to 
administer it intramuscularly (Galea, 2006; Tobin, 2009)2. Naloxone 
can also be given intranasally, using an atomizer spray, but this 
preparation is not currently licensed for use or available in the UK, 
and there may not be robust evidence as to its efficacy (see 5.3). 
 
5.2. There is US evidence that intranasal naloxone administration is 
safe and effective at reversing opioid overdose in the community 
(Doe-Simkins et al., 2009). Intranasal naloxone may be an 
attractive option in the UK as it would not fall under the same 
regulations as an injectable medicine. It would also eliminate the 
risk of needle-stick injuries from the injectable naloxone 
preparation, needle disposal, and blood-borne virus transmission in 
a population already at greater risk (Doe-Simkins et al., 2009; Kerr 
et al., 2008).     
 
5.3. Other evidence suggests that intranasal naloxone has poor 
bioavailability (the degree and rate at which a drug is absorbed) 
compared with intramuscular naloxone (Dowling et al., 2008). 
Intranasal naloxone may not be as effective as injectable naloxone 
and further research on the efficacy of this route of administration is 
needed Kerr et al., 2008; Clarke et al., 2005). 
 
5.4. The ACMD recognises that intranasal naloxone may be an 
attractive option for some people because it does not require the 
use of needles. The ACMD will continue to monitor any 
development of intranasal naloxone manufacture and licensing in 
the UK, and will review evidence to suggest it is a proven effective 
alternative to injectable naloxone. However, it is not thought to be a 
suitable alternative to injectable naloxone at this time. 
 
  
                                                 
2
 The NTA overdose and naloxone training programme for families and carers, the Scottish national 
naloxone programme, and the Welsh Government’s Take-Home Naloxone programme all trained 
people in how to inject intramuscularly. 
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6.1. The National Treatment Agency (NTA) was tasked to oversee the 
overdose and naloxone training programme for families and carers 
by the Department of Health in 2009, and a report on this was 
published in August 2011 (NTA, 2001a; NTA, 2011b).  
 
6.2. The programme did not focus on the efficacy of giving naloxone as 
a treatment intervention to drug users who have overdosed. The 
pilots aimed to demonstrate how training family members to 
respond to overdoses, including using naloxone, can be 
implemented locally. The NTA programme also did not set out to 
make recommendations on increasing the availability of naloxone, 
or amending current regulations on naloxone’s prescription-only 
status. 
 
6.3. The aims of the NTA programme were to show the benefits of 
training carers to respond to overdoses, and to administer 
naloxone; and to provide a set of practice recommendations for any 
local area wanting to run its own training programme.  
 
6.4. The evaluation had quantitative and qualitative components. The 
quantitative elements comprised data from two questionnaires 
devised by the National Addiction Centre, which the NTA adapted. 
Carers completed questionnaires before training and again three 
months afterwards. The main aim was to see if they had witnessed 
further overdoses and had used naloxone. As there was low 
compliance with carers repeating questionnaires, more useful 
information was captured during interviews with the pilot leads and 
the focus groups. 
 
6.5. Training was provided to 495 people across 16 pilot sites. These 
were a mixture of service user-carers, or as a carer for a service 
user.3  
 
6.6. The main findings from the NTA report were: 
 
i. Naloxone was used 18 times in an opiate overdose situation. In 
two other instances, carers used the training they received while 
taking part in the pilot to successfully revive someone who had 
overdosed, without using naloxone. 
 
ii. There were difficulties in recruiting carers, especially in prison 
and inpatient detox settings. This was for a variety of reasons, 
                                                 
3 
The NTA report states that several pilot sites trained pairs of mutual carers (partners, close 
friends, or housemates), who both received a naloxone supply. Some were former service users no 
longer at risk of overdose themselves, but who cared for somebody at risk. Some carers did not use 
drugs, but cared for a drug using family member.   
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including stigma around drug use and fear of impact on the 
length of a prison sentence.  
 
iii. Pilot sites, carers and service users found training beneficial. All 
felt it made sense to train those people most likely to be present 
when users were taking drugs and running the risk of an 
overdose. This was often family members, but also other users.  
 
6.7. The NTA concluded that there is limited evidence that carers are 
the most appropriate people to receive naloxone training. They 
state that while training carers is beneficial in itself, training service 
users and providing overdose training and naloxone to as many 
people as possible may need to be considered to achieve a wider 
impact on overall fatal and non-fatal overdose rates. This includes 





6.8. The Scottish national naloxone programme has been funded 
centrally since June 2011, although some local areas, for example 
Glasgow, have been providing naloxone for some time already. 
After March 2012, the first statistics regarding the amount of 
naloxone distributed and the numbers trained in using it will be 
available. Findings will be reported to the national naloxone 
advisory group to identify potential barriers to the future of the 
programme.  
 
6.9. Naloxone is now available in almost all Scottish Alcohol & Drug 
Partnerships (ADPs). Anecdotally, uptake of naloxone training and 
provision has not been as high as expected. These are similar to 
findings from the NTA report, especially concerns from prisoners 
who do not want to be recognised as drug users, or who believe 
they will not use drugs again following release. Delays in use have 
occurred as naloxone kits do not come pre-prepared with a needle 
inside the naloxone kit, so must be hand-assembled. 
 
6.10. Everyone who receives a naloxone supply must have training in 
how to use it. Family and friends of service users are not offered 
naloxone, but they can be offered training in how to use it. ADP and 
health board areas are being trained in how to deliver naloxone 
training themselves.  
 
6.11. In its 2009-10 annual report, the National Forum on Drug-related 
Deaths included a report from the Short Life Working Group 
(SLWG) on Naloxone Supply. It stated that there is an apparent 
anomaly within current regulations that even though naloxone can 
be given by anyone, it is a prescription-only medicine. Naloxone 
should be made available in places where staff routinely have 
contact with large groups of individuals at high risk of overdose. 
Staff should be trained to provide emergency basic life support and 
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be provided with naloxone for immediate use before ambulance 
services arrive. This includes non-health staff in services such as 
homeless hostels or supported accommodation, outreach services 
and other non- NHS sites and agencies.  
 
6.12. The SLWG requested a ‘letter of comfort’ from the Scottish Lord 
Advocate, which would enable supplies to be made to identified 
groups of staff working with ‘at risk’ drug users who have completed 
naloxone and basic life support training programmes to hold stocks 
of naloxone for use in emergencies (Scottish Government, 2010). 
 
6.13. The Lord Advocate considered that naloxone should be widely 
available in order for the Scottish national naloxone programme to 
be run efficiently. In March 2011, the Scottish Lord Advocate issued 
a guideline that approves authorised prescribers to supply naloxone 
to individuals likely to come into contact with those at risk of opiate 
overdose (Annex C).  
 
6.14. Supporting the national naloxone programme and the Lord 
Advocate’s Guideline is guidance from the Scottish Care 
Inspectorate (Rees et al., 2011). This guidance states that services 
in contact with drug users, with no other means of holding stocks of 
naloxone, are allowed to hold naloxone, such as homeless hostels 
which would not normally be allowed to stock prescription-only 
medicines. In services which have seen overdoses and staff have 
experience of managing overdoses until emergency services arrive, 
staff can use naloxone to aid their response to overdoses.  
 
6.15. This means the national naloxone programme is able to be run in 
appropriate services based a needs assessment. All staff who 
might use naloxone must undertake appropriate basic life support 
training, as specified by the Scottish Government’s Drugs Policy 
Unit. This does not mean naloxone is a personal supply to a named 
worker. Workers receive the naloxone and training in how to use it 
on behalf of the service for storage, and use within the service. 
Naloxone can be used within the range of service provision that a 
service might undertake, including outreach work or residential 
services. 
 
6.16. Glasgow Addiction Services, in conjunction with the Care 
Inspectorate, has produced guidance for non-NHS services in 
contact with people at risk of opiate overdose (Glasgow Addiction 
Services, 2011). This provides background information on the 
national naloxone programme, and has points for consideration by 
service managers in developing a policy regarding take home 
naloxone within their service. It can be adapted for different local 
areas, and has practical advice around auditing naloxone use.  
 
6.17. A range of services have been supplied under the national 
naloxone programme, but the majority are residential as this is 
where the majority of overdoses occur. These include a housing 
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support project where outreach workers already carried a first aid 
pack, and where they had recent experience of having to manage 
overdoses and call the ambulance. 
 
6.18. The implications of the Lord Advocate’s Guideline and Care 
Inspectorate guidance are that naloxone is being distributed to a 
greater number of people, who are in a position to assist someone 
who has overdosed. Naloxone remains a prescription-only 
medicine. Authorised prescribers who supply naloxone to service 
workers, rather than named patients, are also immune from 
prosecution under the Lord Advocate’s Guideline. 
 
6.19. The Scottish government do not consider that over-the-counter 
provision would be an appropriate option within the context of its 
national naloxone programme. It considers there would be no 
assurance that someone had been appropriately trained in how to 
use it. A prescription requirement, and provisions under the Lord 
Advocate’s guideline, allows the government to evaluate the 
programme, monitor the amount distributed and whether it is used, 





6.20. The Welsh Government launched the Take Home Naloxone (THN) 
demonstration project in selected areas in September 2009. This 
was to test the feasibility of expanding the scheme nationwide 
(Annex D). The evaluation recommended a national naloxone 
programme be rolled out with further delay (Bennett et al., 2011). 
 
6.21. As a result of the evaluation findings, the Welsh Government’s 
strategy for tackling substance misuse “Working together to reduce 
harm” has a commitment to take actions which focus on reducing 
the number of drug related deaths and near fatal drug poisonings. 
On the back of the recommendations from the evaluation, one of 
the key actions contained in the strategy’s 3 year implementation 
plan is the development of guidance and protocols to introduce take 




The N-ALIVE trial – England 
 
6.22. The N-ALIVE (NALoxone InVEstigation) trial is a large prison-based 
randomized controlled trial, designed to test the effectiveness of 
giving naloxone-on-release to prisoners with history of heroin use to 
prevent fatal opiate overdoses.  
 
6.23. The N-ALIVE trial is divided into two stages; the pilot randomized 
trial and the subsequent main randomised trial. The pilot trial aims 
to demonstrate feasibility by recruiting the first 10% of participants 
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(5,600 participants). The main N-ALIVE trial will assess the number 
of lives that could be saved by routine provision of naloxone-on-
release to adult prisoners aged 18-44 years with a history of heroin 
injection who are released after seven or more days in prison 
(whether post-detoxification, on maintenance treatment, or 
otherwise). The pilot trial includes an ancillary study in which the 
participants who give their additional consent will be contacted once 
by phone. This sub-study will allow collection of further information 
on opiate use, overdoses, and naloxone use soon after release.  
 
6.24. Eligible prisoners who give informed consent will be randomised to 
receive, on release from custody, either a pack containing a single 
‘rescue’ injection of naloxone or a control pack containing no 
naloxone. The trial is ‘double-blind’ prior to the participant’s release 
so that neither the participant nor prison staff will know the 
allocation until the participant opens his/her assigned pack after 
release (King’s College London, 2012). 
 
6.25. The trial has received ethical approval, and has funding from the 
Medical Research Council (MRC). It will be carried out by the 
MRC’s Clinical Trials Unit and will be run in English prisons only, 
due to the Scottish and Welsh programmes both operating already 
in prisons as well as the community.  
 
6.26. The investigators have estimated the impact of the N-ALIVE trial as 
follows. Evidence suggests that in the first four weeks, there is one 
overdose death out of every 200 injectors released from prison. The 
following assumptions have been made: 
 
i. Assumption 1: someone else is present at 80% of overdoses  
ii. Assumption 2: there is a 75% chance a prisoner will retain their 
naloxone in the first four weeks of release  
iii. Assumption 3: there is a 50% chance a prisoner will retain their 
naloxone in the proceeding eight weeks following release  
iv. Assumption 4: there is a 50% chance that naloxone will be 
administered by someone else at the overdose 
v. This means the effectiveness of naloxone is estimated to be 
about 30% in the first four weeks following release from prison. 
The estimated effectiveness of naloxone falls to 20% in the fifth 
to twelfth weeks following release 
vi. This means that the distribution of naloxone in the N-ALIVE trial 
could prevent 42 drug deaths in first and second fortnight per 
28,000 who inject drugs when they are released from prison. 
 
6.27. Because deaths in England do not need to be registered in the year 
they occur, this may affect how soon N-ALIVE can find out about 
drug-related deaths of ex-prisoners involved in the trial. At the time 
of writing, prisons were being recruited to take part in the trial. 
Findings are not expected to be available for some years.  
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7. Effectiveness of naloxone provision 
 
7.1. Naloxone can be used by laypeople with the right training, and 
there is an easy prescribing system. Because many overdoses are 
witnessed, there is the potential for people to intervene and try to 
save lives.  
 
7.2. The effectiveness of take-home naloxone programmes on drug-
related death rates may be difficult to prove, especially if the 
majority of overdoses are estimated to be non-fatal. Local areas 
may be able to make estimates based on local overdose and drug-
related death rates.  
 
7.3. The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) estimate that for every fatal overdose, there are up to 
25 non-fatal overdoses that occur in Europe. Available information 
suggests that there are around 150,000 non-fatal overdoses every 
year in Europe (EMCDDA, 2010). There are no available estimates 
for the UK only. 
 
7.4. Overdose is a real risk for those who inject opiates, and between 
half and three-quarters of overdoses are witnessed, by people who 
are willing to help (Strang et al., 2008). Sometimes these include 
family members. Periods of increased risk follow imprisonment, and 
when someone has just begun or stopped receiving opioid 
substitution treatment or after detoxification. 
  
7.5. There is no way to know for sure, in individual cases, what effect 
naloxone may have on a person’s survival. An overdose reversal 
occurring after receiving naloxone may not be because a person 
has received naloxone. It may be due to life support interventions, 
or whether or not they were in an overdose state to begin with. This 
emphasises the importance of providing basic life support and 





7.6. There is a lack of published research on the cost-effectiveness of 
naloxone provision (NTA, 2011a). Naloxone provision in local areas 
would therefore be a local decision including an assessment on its 
cost-effectiveness. 
 
7.7. The N-ALIVE trial investigators have shown that their provision of 
naloxone to inmates on release would meet NICE clinical 
effectiveness thresholds. For example, the threshold is £20,000 per 
life year gained, and if naloxone is able to prevent 42 drug deaths in 
the first and second fortnight per 28,000 injectors released, then 
naloxone is cost-effective, as it would cost £30 per naloxone 
prescription/per inmate.  
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7.8. The Scottish Government reimburses £10.95 per naloxone kit to 
health boards providing training and naloxone. This includes: 
 
 A plastic box 
 A 2ml pre-filled naloxone 1mg/ml syringe (contains five doses)  
 2 x 23 gauge 1¼  inch muscle needles 
 Patient Information Leaflet  
 
 
7.9. This does not cover the cost of training, which would vary between 
different regions and services. The Scottish Government is yet to 
decide whether its programme will be evaluated for cost-
effectiveness. If they do, findings will take some years to produce. 
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8. Worldwide evidence  
 
8.1. Naloxone has been available directly to users, or from training 
programmes in several countries worldwide, in different forms, for 




8.2. Naloxone has been provided via training programmes in the United 
States for the last two decades. Naloxone training programmes 
have improved participants' ability to recognize and respond to 
opioid overdoses in the community. Drug users with overdose 
training and confidence in their abilities to respond may effectively 
prevent overdose mortality, compared with those who have 
received no training (Green et al., 2008).  
 
8.3. Research into 48 US naloxone trials and programmes has found 
that distribution of naloxone and training in its administration may 
have prevented numerous deaths from opioid overdose (CDC, 
2012). 
 
8.4. Peers are willing to respond in an overdose situationand naloxone 
distribution may have an impact on overdose mortality rates 
provided with or within the context of a wider overdose prevention 
programme (Lagu et al., 2006). In Cook County, Chicago, the 
introduction of and sustained widespread naloxone distribution 
coincided with a noticeable decrease in drug-related deaths 
between 2000 and 2007 (Guteson, 2010). 
 
8.5. Some US states have passed laws and changed regulations to 
provide limited liability for prescribers who work with programs 
providing naloxone to laypersons. Other states have enacted Good 
Samaritan laws providing protection from arrest in an effort to 
encourage bystanders at a drug overdose to phone emergency 





8.6. A recent Australian study concluded that naloxone had the potential 
to reduce opiate overdose mortality and morbidity among injectors. 
There was strong support for peer distribution programmes and 
intranasal formulations.  Naloxone can only be prescribed directly to 
an individual for use on them, as in the UK. Naloxone’s prescription-
only status could limit access, but there are precedents in 
prescription medication regulations which are already established, 









8.7. Naloxone was made available over-the-counter to heroin users in 
the Emilia-Romagna region of Italy in 1998 (Simini, 1998; Baca et 
al., 2005). The ACMD is not aware of published findings on the 
effectiveness of this programme. 
 
 
Regulation of naloxone supply 
 
8.8. In the US, naloxone is subject to similar legal and medical controls 
as in the UK and Australia. It is available on prescription to named 
individuals. There have been calls for the requirement for a 
prescription to be lifted, as it has no abuse potential, has side 
effects limited to withdrawal symptoms, and can be used by 
laypeople without doctor’s supervision (Beletsky et al., 2009). The 
cost of hiring a medical professional to provide prescriptions could 
be prohibitive for programmes which have limited funding.   
 
8.9. Legal concerns, especially to do with malpractice or liability, may 
have presented barriers to implement naloxone programmes more 
widely across the US (Beletsky et al., 2009). Other evidence 
suggests that risks of malpractice are similar to those normally 
found when providing other forms of healthcare (Burris et al., 2001).  
 
8.10. Naloxone’s prescription-only status in the US may have further 
implications than it does in the UK, but this may relate more to the 
potentially prohibitive cost of involving medical personnel to assess 
patients and write prescriptions. There may be different cost 
implications in the UK due to the provision of publically-funded drug 
treatment by the NHS.  
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9. Potential for misuse or abuse of naloxone 
 
9.1. Naloxone brings on temporary withdrawal symptoms in an 
individual who has opioids in their system, but on people who do 
not have opioids in their system, there are no such withdrawal 
effects. Naloxone has no intoxicating effects or dependence-
forming potential.  
 
9.2. Side-effects are rarely reported. When side-effects have occurred, 
they were mostly associated with pre-existing medical conditions 
(Bryson, 1996; Sporer et al., 2007). They are also associated with 
significantly higher dose levels than those used in peer overdose 
interventions. Peer training programmes do not report side effects, 
probably because peers are trained to give small doses of naloxone 
(Burris et al., 2001). 
 
9.3. The ACMD is aware of concerns that naloxone provision could 
encourage increased or riskier drug use (Travis, 2011), or even 
malicious administration, to induce withdrawal symptoms on 
purpose.  
 
9.4. While there is a risk that opioid users may increase their use if 
naloxone is there as a ‘safety net’, and that concern about the risk 
of increased harm from drug use is legitimate, there is no published 
evidence to prove this. Recent US evidence does not support the 
claim that naloxone provision could encourage increased or riskier 
drug use (Maxwell et al., 2006; Seal et al., 2005; Wagner et al., 
2010). Some studies have in fact have found decreased drug use 
(Seal et al., 2005; Wagner et al., 2010). Some authors argue it is 
not useful to focus on the harms of drug use when compared with 
an opportunity to intervene and potentially save lives (Bazazi et al., 
2010). 
 
9.5. Expert opinion was supplied to the ACMD by UK naloxone expert 
Professor John Strang:  
 
“There is merit in the training of family and the peer community in 
essential steps to be taken in the event of discovering or observing 
a heroin overdose, including the importance of calling an 
ambulance and initiating ‘rescue breathing’ if breathing is 
compromised. In this context, the additional administration of an 
interim dose of intramuscular naloxone may maintain life support 
until the arrival of medical or para-medic staff.  
 
Evidence from training of both family and peers is that training in 
overdose management (including how to administer emergency 
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9.6. Professor Strang also notes: 
 
i. There are concerns that naloxone provision could create a 
perception of greater safety, and lead to excessive heroin 
use. The response of emergency services with ambulance 
call-out might similarly generate a perception of greater 
safety. Professor Strang is not aware of any significant body 
of evidence that this leads to excessive heroin use. 
 
ii. Furthermore, as with other preventive medicine interventions, 
these concerns must be balanced against the life-threatening 
nature of the situation that is being addressed, including 
whether it is better to supply naloxone in case of overdose 
rather than not supply it because of these concerns.  
 
iii. A well-designed research trial which measures the actual 
impact on overdose deaths will answer some of these 
questions, such as the current N-ALIVE trial. It is important for 
these questions to be answered objectively, and carefully-
considered and well-designed trials will contribute to the 
development of improved policy and practice.  
 
9.7. There is a considerable body of published evidence, mostly from 
the UK and Australia, to suggest people would not use more heroin, 
if naloxone was available (Darke et al.,1996; Lenton et al., 2000; 
Gaston et al., 2009; Strang et al., 1996). Participants in naloxone 
programmes have been found to have an “increase in self efficacy 
and more insight in relation to personal safety and health”. Users 
would not wish to induce unpleasant withdrawal symptoms, and the 
availability of naloxone does not promote a ‘false sense of security’ 
leading to an increase in heroin use (Gaston et al., 2009). 
 
9.8. The ACMD is not aware of evidence to support the claim that a fear 
of instigating withdrawal would lead to someone being unwilling to 
give naloxone. Nor is the ACMD aware of published evidence which 
has found an increased risk of inappropriate or malicious use of 
naloxone, which could raise issues of liability (Gaston et al., 2009). 
The ACMD is not aware of evidence to suggest people have 
administered naloxone maliciously to bring on withdrawal symptoms 
in someone else.  
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10.  Liability issues 
 
10.1. Naloxone provision has been subject to recent debates and 
challenges in the UK. These include the question of individual 
liability if naloxone is used ‘unsuccessfully’; that is, if the person on 
whom it was used is not revived, has been questioned. Also, 
whether greater naloxone availability, for example in hostel settings, 
might lead to naloxone over-use due to fear of being held liable if 
someone died (Flemen, 2011). Furthermore, it has been speculated 
that people trained in administration of naloxone may not always 
make a correct judgment as to whether a potentially fatal overdose 
has occurred before they use naloxone.  
 
10.2. The ACMD have identified that issues of liability and negligence 
may arise both currently, and if provision is extended. If the ACMD’s 
recommendations are accepted, it would be a matter for 
government policy units to assess the risks and benefits associated 
with liability, and appropriate advice given to practitioners and 
individuals trained to administer naloxone.  
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11. Conclusions and Recommendations 
 
11.1. There are more than one thousand fatal opioid overdoses in the UK 
each year, which could be prevented by naloxone. Evidence shows 
that providing naloxone has benefits that include, but are not limited 
to, a reduction in opioid-related deaths.  
 
11.2. Opportunities to assist unnamed individuals in an overdose 
situation with naloxone are limited by its prescription-only status. It 
cannot supplied directly to individuals who have a good opportunity 
to intervene in an overdose, such as hostel staff. 
 
11.3. The balance of benefit around providing naloxone, and the 
opportunities for reversing overdoses and saving lives, is greater 
than any potential risks. Risks and concerns around malicious use 
of naloxone, or the potential for users to be more reckless with their 
drug use, are not supported by evidence.  
 
Recommendation 1: Naloxone should be made more widely 
available, to tackle the high numbers of fatal opioid overdoses 
in the UK. 
 
11.4. The ACMD commends the Lord Advocate's Guideline, and the Care 
Inspectorate guidance, which are already allowing wider provision 
of naloxone in Scotland. It would be timely to review the marketing 
authorisation of naloxone by the Medicines and Healthcare 
Products Regulatory Agency as a prescription-only medicine. 
 
Recommendation 2: Government should ease the restrictions 
on who can be supplied with naloxone 
 
11.5. Training carers in naloxone administration may be beneficial, but 
training all those likely to encounter an overdose would have a 
greater impact on overdose rates. 
 
11.6. Naloxone availability to a wider group of people will further highlight 
the risks of opioid overdose, and have educational and public health 
benefits.  
 
11.7. Naloxone provision is just one of several tools in a package of 
interventions to prevent opioid overdose. These include basic life 
support training. It is important that individuals possessing naloxone 
are given suitable training in how to respond to an overdose, as well 
as administer naloxone. 
 
Recommendation 3: Government should investigate how 
people supplied with naloxone can be suitably trained to 
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Annex A  
 
ACMD 
Advisory Council on the Misuse of Drugs 
 
Chair: Professor David Nutt 
Secretary: Will Reynolds  
3rd Floor Seacole Building  
2 Marsham Street  
London  
SW1P 4DF  
020 7035 0454 
Email: ACMD@homeoffice.gsi.gov.uk  
 
12th October 2009  
 
Medicines and Healthcare products Regulatory Agency 
Market Towers  
1 Nine Elms Lane  




Dear Mr Gallagher  
 
Thank you for your response of 27 May 2009 to the Advisory Council on the 
Misuse of Drugs (ACMD) Technical Committee’s correspondence in relation 
to the provisions of naloxone.   
 
The ACMD welcomes the National Treatment Agency’s (NTA) pilot scheme 
announced earlier this year; which provides family members and carers 
training and supplies of naloxone for heroin users in the event of an overdose. 
The ACMD believe that this represents a step forward in tackling the high 
numbers of fatal opiate overdoses.  
 
However, although the ACMD believe this to be movement of policy in the 
right direction we consider that provisions should be extended to cover others 
who may be in contact with drug users through their work such as hostel 
managers or outreach drugs workers. We would also recommend that it 
should be made possible for (suitably trained) drug service providers such as 
needle exchanges and outreach programmes to be able to hold/carry a stock 
of naloxone for use in an emergency and to consider allowing such services, 
for example, pharmacy needle exchanges to be able to issue repeat supplies 
of naloxone without the need for a prescription or a PGD. It should be noted 
that many drug services, particularly tier 2 services, may not have a nurse, 
doctor or pharmacist on their premises or in their employ and there is not a 
professional qualification of “drug worker”. 
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The ACMD acknowledge naloxone’s present Prescription Only Medicine 
(POM) status (and availability through a Patient Group Direction). However, 
the Committee remains concerned about availability issues. The Technical 
Committee believes that it would be reasonable for drug service providers to 
hold supplies of naloxone for unnamed individuals and for it to be 
administered by trained individuals in the event of an overdose. Further the 
Technical Committee believes that there is an analogy between naloxone 
provisions and a House of Lords report recommendation concerning allergies; 
in which it was recommended that the Government should review the case for 
schools holding one or two adrenaline autoinjectors to be administered to 
children with anaphylactic shock in the school environment, the report can be 
found at 
http://www.publications.parliament.uk/pa/ld200607/ldselect/ldsctech/166/166i.
pdf (section 10.26).   
 
Although the NTA identifies that many drug misusers live with family members 
and that overdoses occur within these environments it is important that other 
elements of drug misusers’ lives are appropriately catered for. Although 
relatives and carers are an important group to be considered, the ACMD 
believe that wider provision, of what is a specific and safe chemical, and could 
provide benefits.   
 
The ACMD also believe that the standard prescription fee should be waived 
for naloxone when supplied on a NHS prescription or under a PGD as occurs 
for other certain medicines such as those used for treatment of sexually 
transmissible infections, for treatment of TB etc. 
 
I would appreciate if you would consider the view of the ACMD in relation to 



































LORD ADVOCATE’S GUIDELINES 
ON ALLOWING THE SUPPLY OF NALOXONE TO EXTEND TO STAFF 
WORKING FOR SERVICES IN CONTACT WITH PEOPLE AT RISK OF 
OPIATE OVERDOSES 
 
Naloxone is a prescription only medicine (POM) used to temporarily reverse 
some of the effects of an opiate overdose – primarily respiratory depression. 
 
Essentially, this medication provides extra time for an ambulance to arrive 
(around 20 minutes) and treatment to be provided. An amendment to the 
Medicines Act 1968 in 2005 means that now anyone can legally administer 
naloxone to save a life. However the supply of this medication by health 
professionals is restricted to named patients only. 
 
The roll out of a National Naloxone Programme (hereafter ‘the Programme’) is 
due to commence in September 2010. The Programme involves services 
which come into contact with those deemed at risk of an opiate overdose 
being provided with their own supply of the medication. Those in a position to 
administer naloxone will receive appropriate training to do so.  
 
It is the view of the Lord Advocate that this medication should be widely 
available as soon as possible in order for the Programme to be run efficiently. 
Therefore it is important that authorised persons who are involved in 
supplying services which come into contact with those vulnerable individuals 
who may be at risk of opiate overdose, and who possess naloxone for the 
purpose of administering in emergency situations, are not criminalised for 
doing so. 
 
The Lord Advocate is aware that the Scottish Government is looking into 
amending current legislation to allow authorised prescribers to supply such 
services with the medication. In the meantime the Lord Advocate has 
approved that authorised prescribers be permitted to supply individuals likely 
to come into contact with those at risk of opiate overdose with the medication 
without risk of prosecution. In accordance with this guidance, such authorised 
prescribers will therefore be immune from prosecution. 
 
This undertaking has been given by the Lord Advocate on the basis that the 
supplies of the medication by authorised prescribers to such members of staff 
will only be used for administering in emergency situations. Holders of the 
medication are required to undertake appropriate basic life support training, 
as specified by the Scottish Government’s Drugs Policy Unit in rolling out the 
Programme. 
 













RE: ACMD Technical Committee (1) – Tuesday 22nd March 2011 
 
I am pleased to provide below the ACMD technical Committee with the details 
of how we have taken forward the Naloxone initiative in Wales.    
 
NALOXONE INITIATIVE in WALES   
 
The Welsh Assembly Government’s Substance Misuse Strategy, 
three Year Implementation Plan 2008-11 set an objective to maintain a 
commitment to reducing Drug Related Deaths.  As part of that commitment 
the Welsh Assembly Government supported the introduction of the use of 
Naloxone in Wales.   
 
In 2009 a National Working Group was established by The Welsh Assembly 
Government to oversee the establishment of demonstration sites across 
Wales to deliver this initiative.    
 
The Demonstration sites were established in Newport, Cardiff, Swansea, 
North Wales and Swansea, Cardiff, Parc and Usk prisons. This decision was 
based upon drug related death data showing these areas as particular 
hotspots.    The sites became operational in August 2009.  To date 684 
Naloxone kits have been issued with 51 being used in an attempt to reverse 
opiate overdose.   
To:   Ali Mohammed  
Advisory Council on the Misuse of 
Drugs (Secretariat)   
Home Office   
Floor 3, Seacole Building 
2 Marsham Street 
London 
SW1P 4DF  
 
 





CC:  Dr Gwyn Roberts, Chair 
APoSM 
 Karen Eveleigh  
Welsh Assembly Government   
Rhydycar 




                  Date :   9/March 2011 
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Each site has implemented the initiative in a slightly different way according to 
local circumstances, but in each area, training is provided in identifying and 
recognising the symptoms of overdose, exploding the myths around what to 
do and providing basic first aid training.  This is then followed by training in the 
use of Naloxone and practising injecting.   The training has presented a key 
challenge in terms of ensuring the session length is enough to provide all of 
the information whilst maintaining interest.  Each area targeted existing 
service users and “hard to reach” groups, their families and carers.   The 
initiative was under-pinned by national guidance which can be accessed at: 
(http://wales.gov.uk/topics/housingandcommunity/safety/substancemisuse/pu
blications/naloxone.   
 
A bespoke Naloxone kit for Wales was developed and purchased centrally for 
“draw down” at the local level.  The bespoke kit was developed via the 
National Working Group, the basis for this kit was cost effectiveness, current 
availability of Naloxone and due to the fact that the kit is sealed and 
childproof.   
 
The initiative has been subjected to an external evaluation by the University of 
Glamorgan.  The researchers worked closely with a wide range of 
stakeholders across the demonstration sites including service providers and 
services users to conduct a process and outcome evaluation.  The main 
intention of the evaluation was to identify good practice and “learn lessons” 
from the demonstration sites to inform the national roll-out of the project.  The 
evaluation has recently be finalised and will be published shortly.  Interim 
results show that service users who had attended the Naloxone training 
displayed increased knowledge, confidence and a willingness to recognise 
and respond to overdose situations.  The training impacted positively on the 
confidence of individuals to administer Naloxone, with over 90% of 
respondents stating that they were ‘very confident’ in carrying out the task.   
 
The next step is to publish the evaluation report and consider roll-out of the 
project across Wales.  If you need further information please do not hesitate 
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